232 completed, 32 unknown, 30 recruiting, 20 terminated. 331 Phase 3, 31 Phase 2.
Follow Herpesviridae Infections: new trials by email Literature Review of Herpesviridae Infections trials Research Report on Herpesviridae Infections
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma Biospecimen Collection, Bone Marrow Biopsy, Carboplatin - Recurrent Burkitt Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements | Phase 2 / Phase 3 | Not yet recruiting | National Cancer Institute (NCI) | 271 | 2026-10-30 | 2026-08-19 |
| Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies IgPro20 - Secondary Immune Deficiency | Phase 3 | Recruiting | CSL Behring | 63 | 2026-09-15 | 2026-10-14 |
| International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020) Inotuzumab ozogamicin (INO), Blinatumomab - B-Cell Acute Lymphoblastic Leukaemia | Phase 3 | Recruiting | Charite University, Berlin, Germany | 750 | 2026-09-01 | 2026-10-26 |
| Paclitaxel and Pegylated Liposomal Doxorubicin for Treatment of HIV-related Kaposi Sarcoma Pegylated liposomal doxorubicin, Paclitaxel - Kaposi Sarcoma, HIV-1-infection | Phase 3 | Not yet recruiting | AIDS Malignancy Consortium | 130 | 2026-09-01 | 2026-01-23 |
| Immunoglobulin Replacement Therapy (IgRT) Versus Antibiotic Prophylaxis (PA) in Patients Treated by CD19-targeted Chimeric Antigen Receptor (CAR)T Cells for a B Cell Acute Lymphoblastic Leukemia or a B Cell Lymphoma Immunoglobulin, antibiotic prophylaxis - Chimeric Antigen Receptor T-cell Therapy, B Cell Acute Lymphoblastic Leukemia (B-ALL) | Phase 3 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 228 | 2026-09-01 | 2026-08-10 |
| Phase 3 Randomized Trial for Refractory ADV or CMV Infection With Family Matched CTLs and Standard of Care (SOC) vs SOC Alone Standard of Care Antiviral medications, Viral CTLs - CMV, AdV Infection | Phase 3 | Recruiting | New York Medical College | 138 | 2026-09-01 | 2026-09-11 |
| BRIDGE-NK: Immunotherapy Versus Chemotherapy Induction Followed by Autologous HSCT in Advanced NKTCL GELAD regimen, MEDA regimen, LEAP regimen - Extranodal NK/T-cell Lymphoma | Phase 3 | Recruiting | Rong Tao | 150 | 2026-08-11 | 2026-08-13 |
| A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Given to Healthy Children 4 to 6 Years of Age MMRVNS vaccine, MMRV vaccine, DTaP-IPV vaccine - Measles, Mumps | Phase 3 | Not yet recruiting | GlaxoSmithKline | 1860 | 2026-08-11 | 2026-08-03 |
| SkyVaricella® (NBP608) Vaccine With Lower Potencies in Healthy Children Aged 12 Months to 12 Years NBP608 (Mid Potency), NBP608 (Low Potency), Varivax® - Varicella (Chickenpox) | Phase 3 | Recruiting | SK Bioscience Co., Ltd. | 780 | 2026-07-04 | 2026-09-15 |
| Phase III Clinical Trial of Lyophilized Herpes Zoster mRNA Vaccine in Adults Aged 40 Years or Above ABO1108, Placebo - Varicella-zoster Virus | Phase 3 | Recruiting | Suzhou Abogen Biosciences Co., Ltd. | 18000 | 2026-06-27 | 2026-09-14 |
| Immunogenicity and Safety of Varicella Vaccine, Live in Healthy Vietnamese Children Varicella Vaccine - Varicella (Chickenpox), Varicella Immunisation | Phase 3 | Not yet recruiting | Sinovac (Dalian) Vaccine Technology Co., Ltd. | 300 | 2026-06-15 | 2026-06-12 |
| A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005) MK-1045, Blinatumomab, Acetaminophen - B-cell Acute Lymphoblastic Leukemia | Phase 2 / Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 340 | 2026-05-18 | 2026-10-30 |
| A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Administered as Intramuscular Injection to Healthy Children 15 Months to 6 Years of Age MMRVNS, MMRV - Measles, Measles-Mumps-Rubella+Chickenpox Vaccine | Phase 3 | Recruiting | GlaxoSmithKline | 1209 | 2026-05-11 | 2026-07-08 |
| A Study to Evaluate Immunogenicity and Safety After the First and Second Doses of MG1111 (BARYCELA Inj.) in Healthy Children Aged 12 Months to 12 Years MG1111 (Barycela inj.), VARIVAX™ - Varicella (Chickenpox), Chickenpox Vaccine | Phase 3 | Recruiting | GC Biopharma Corp | 474 | 2026-03-17 | 2026-04-17 |
| Second Dose of Varicella Vaccine in Healthy Children PROVARIX - Varicella (Chickenpox), Varicella Immunisation | Phase 3 | Recruiting | Sinovac (Dalian) Vaccine Technology Co., Ltd. | 300 | 2026-01-28 | 2026-03-16 |
| A Phase III Clinical Trial to Evaluate Long-Term Protective Efficacy of Recombinant Zoster Vaccine (CHO Cell) Recombinant Zoster Vaccine (CHO Cell), NaCl solution Placebo - Herpes Zoster | Phase 3 | Active not recruiting | MAXVAX Biotechnology Limited Liability Company | 12000 | 2025-12-15 | 2026-10-15 |
| A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia Fludarabine, Cyclophosphamide, CAR-T - B-cell Acute Lymphoblastic Leukemia | Phase 3 | Recruiting | Memorial Sloan Kettering Cancer Center | 130 | 2025-10-20 | 2026-10-05 |
| Steroids for Facial Nerve Function Protection in Post-surgical Vestibular Schwannoma Patients Steroids therapy, Placebo - Vestibular Schwannoma, Facial Nerve Paralysis | Phase 3 | Recruiting | Beijing Tiantan Hospital | 364 | 2025-10-09 | 2026-10-26 |
| NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19) Talikabtagene Autoleucel - Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL), Relapsed/Refractory Non-Hodgkin Lymphoma | Phase 2 / Phase 3 | Recruiting | Health Institutes of Turkey | 40 | 2025-09-11 | 2026-03-30 |
| A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Healthy Children 3 Months After a First Dose at 12 to 15 Months of Age Investigational varicella vaccine, Marketed varicella vaccine, MMR vaccine - Chickenpox | Phase 3 | Recruiting | GlaxoSmithKline | 600 | 2025-05-15 | 2026-05-29 |
Showing 20 of 331. Sign in to see all of them.
Burkitt Lymphoma (76) · Herpes Zoster (66) · Chickenpox (64) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (49) · Lymphoma, Large B-Cell, Diffuse (47) · Cytomegalovirus Infections (46) · Lymphoma, Follicular (43) · Lymphoma, Non-Hodgkin (42) · Lymphoma, Large-Cell, Immunoblastic (40) · Lymphoma, Mantle-Cell (40) · Lymphoma (39) · Lymphoma, B-Cell, Marginal Zone (37) · Leukemia, Lymphocytic, Chronic, B-Cell (36) · HIV Infections (35) · Herpes Simplex (34)
DNA Virus Infections (330) · Virus Diseases (325) · Infections (321) · Varicella Zoster Virus Infection (126) · Immune System Diseases (117) · Neoplasms by Histologic Type (90) · Tumor Virus Infections (89) · Hemic and Lymphatic Diseases (83) · Neoplasms (81) · Lymphatic Diseases (80) · Immunoproliferative Disorders (78) · Epstein-Barr Virus Infections (77) · Lymphoma, B-Cell (74) · Lymphoproliferative Disorders (72)
Cyclophosphamide (27) · Vincristine (25) · Acyclovir (24) · Doxorubicin (24) · Valganciclovir (19) · Herpes Zoster Vaccine (18) · Methotrexate (17) · measles, mumps, rubella, varicella vaccine (17) · Dexamethasone (16) · Prednisone (16) · Cytarabine (15) · Etoposide (15) · Radiotherapy (14) · Ganciclovir (13) · Valacyclovir (13)
GlaxoSmithKline (47) · Merck Sharp & Dohme LLC (37) · National Institute of Allergy and Infectious Diseases (NIAID) (14) · Children's Oncology Group (8) · National Cancer Institute (NCI) (7) · Sinovac (Dalian) Vaccine Technology Co., Ltd. (7) · Hoffmann-La Roche (5) · Johns Hopkins Bloomberg School of Public Health (5) · National Center for Research Resources (NCRR) (5) · Fred Hutchinson Cancer Center (4) · German High-Grade Non-Hodgkin's Lymphoma Study Group (4) · NeurogesX (4) · Novartis Pharmaceuticals (4) · Sanofi Pasteur, a Sanofi Company (4) · Sequus Pharmaceuticals (4)
United States (155) · Canada (63) · Germany (41) · France (39) · Italy (35) · United Kingdom (34) · Australia (33) · Belgium (26) · China (26) · Spain (26) · Czechia (20) · Sweden (18) · Japan (17) · Netherlands (16) · South Korea (16)
Connie Celum, MD, MPH (4) · Anna Wald, MD, MPH (2) · Darrell HS Tan, MD FRCPC (2) · David W. Kimberlin (2) · Douglas Jabs, MD (2) · Feinberg J (2) · Hee-Jin Cheong, Ph.D (2) · Hongxing Pan (2)
PMID 37781954, PMID 38700045, PMID 39807668, PMID 36066965, PMID 37166199, PMID 19273678, PMID 21991950, PMID 29955836, PMID 30935742, PMID 31042791, PMID 31537443, PMID 32347767, PMID 32589970, PMID 32665955, PMID 32910152, PMID 33606577, PMID 37890117, PMID 39121442, PMID 40237463, PMID 40396505, PMID 41671463, PMID 10820362, PMID 11919489, PMID 12097537, PMID 12232843, PMID 12559647, PMID 15459300, PMID 15914552, PMID 15930418, PMID 16148284, PMID 16231970, PMID 16282339, PMID 16452343, PMID 16567978, PMID 16804432, PMID 17132719, PMID 17138821, PMID 17397698, PMID 17417658, PMID 17502347, PMID 17617198, PMID 17711594, PMID 17889355, PMID 18008230, PMID 18065407, PMID 18226581, PMID 18256325, PMID 18293016, PMID 18371107, PMID 18419349
U10CA180886 (5), 2015 (4), U10CA098543 (4), 2017 (3), 2018 (3), 2019 (3), 2023 (3), 2025 (3), N01AI30025 (3), U10CA032102 (3), 2009 (2), P01CA015396 (2), P30CA006973 (2), P30CA068485 (2), U10CA180821 (2)